Net loss narrowed and equity ratio improved year-over-year, with strong sales momentum for Efemia in France and NHS listing in the UK. Cash position strengthened following a rights issue, supporting continued growth and product development.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.